Sulbactam·ampicillin in urinary tract infections

Daisuke Yamada, Yositsugu Nasu, Masaya Tsugawa, Mikio Kishi, Hiromi Kumon, Hiroyuki Ohmori, Katsuichi Nanba, Yasuhiro Katayama, Nobuyuki Akazawa, Toshihiko Asahi

Research output: Contribution to journalArticlepeer-review


We clinically investigated a new combination drug, sulbactam·ampicillin (SBT·ABPC) at the ratio 1:2, in the urological field. SBT·ABPC was administered to 24 patients with complicated urinary tract infections at a dose of 1.5 g twice daily for 5 days. The clinical efficacy rate was 75% according to the criteria of the Japanese UTI committee. Bacteriologically, 23 of 29 organisms (79%) were eradicated. There were no subjective side effects, but slight elevation of transaminase was noted in three cases.

Original languageEnglish
Pages (from-to)415-423
Number of pages9
Publication statusPublished - Jan 1 1988

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'Sulbactam·ampicillin in urinary tract infections'. Together they form a unique fingerprint.

Cite this